Related Experiment Video

Updated: Mar 27, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

4.0K

β-Adrenergic Receptors : New Target in Breast Cancer

Ting Wang1, Yu Li, Hai-Ling Lu

  • 1Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Heilongjiang Province, China E-mail : cxs1978@ems.hrbmu.edu.cn; caili@ems.hrbmu.edu.cn.

Asian Pacific Journal of Cancer Prevention : APJCP
|January 9, 2016
PubMed
Abstract

Insights

Beta-blocker use may improve breast cancer prognosis, potentially reducing mortality and metastasis risk. Further large-scale studies are needed to confirm these findings for beta-adrenoceptor blockers in breast cancer patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiology

Background:

  • Preclinical data suggest beta-adrenergic receptor antagonists may improve breast cancer outcomes.
  • Clinical and pharmacoepidemiological studies show inconsistent results regarding beta-blocker use and breast cancer prognosis.

Purpose of the Study:

  • To re-evaluate the association between beta-adrenoceptor blockers and breast cancer prognosis.
  • To synthesize evidence from existing literature on beta-blocker drug use and patient outcomes in breast cancer.

Main Methods:

  • Systematic literature search of PubMed, EMBASE, and Web of Nature databases.
  • Inclusion of studies investigating beta-adrenoceptor blockers and breast cancer prognosis.
  • Key search terms included 'breast cancer' and 'beta-adrenoceptor blockers'.

Main Results:

  • Six of ten studies indicated reduced breast cancer-specific mortality with beta-blocker use.
  • Two studies reported significant reductions in recurrence and distant metastasis risk.
  • One study showed increased relapse-free survival, while overall survival association was not consistently significant.

Conclusions:

  • Beta-adrenoceptor blocker use may be linked to improved breast cancer prognosis.
  • Evidence suggests potential benefits in reducing mortality and metastasis.
  • Larger studies are required to definitively establish the relationship between beta-blocker use and breast cancer outcomes.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System10:51

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Published on: April 23, 2021

4.7K

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.4K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
5.6K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.2K
Sympathetic Signaling01:31

Sympathetic Signaling

Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
3.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K